High-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 39 advanced ovarian cancers: long-term results

Commun epithelial ovarian carcinoma, in particular stage III and IV (FIGO) have a poor prognosis with a survival rate < 20 % at 5 years. Paradoxically ovarian cancer is very responsive to chemotherapy with high overall response rates demonstrated consistently using Cisplatin based combination regimens. It is this contrast of high response rates with major reductions in tumor burden, yet low numbers of durable complete remissions, that let us to use a high-dose chemotherapy and ABMT in poor risk patients.